Represent Fortune 500 biopharmaceutical company in various matters, including leading the IP due diligence, Freedom to Operate (FTO) analysis, and patentability analysis for two biotech-based company acquisitions valued at $350 million and $400 million respectively. Continue to develop and manage the patent portfolio for each of these two acquisitions, including on-going FTO and patentability analysis, as well as development of overall life cycle management strategies.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.